Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 12,000 shares of the firm’s stock in a transaction on Monday, October 17th. The shares were sold at an average price of $113.95, for a total transaction of $1,367,400.00. Following the transaction, the director now owns 193,142 shares in the company, valued at approximately $22,008,530.90. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Stryker Corp. (NYSE:SYK) opened at 113.57 on Tuesday. The stock’s 50 day moving average is $115.20 and its 200 day moving average is $114.25. Stryker Corp. has a 12 month low of $86.68 and a 12 month high of $123.55. The firm has a market cap of $42.51 billion, a PE ratio of 26.77 and a beta of 0.72.

Stryker Corp. (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.37 by $0.02. The company earned $2.84 billion during the quarter, compared to the consensus estimate of $2.79 billion. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. Analysts forecast that Stryker Corp. will post $5.76 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Stryker Corp. (NYSE:SYK)

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be given a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Wednesday, September 28th. Stryker Corp.’s dividend payout ratio (DPR) is 35.85%.

A number of research firms recently issued reports on SYK. Jefferies Group reiterated a “hold” rating and issued a $120.00 target price (up from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $119.00 target price on shares of Stryker Corp. in a research note on Friday, July 22nd. Credit Suisse Group AG reiterated an “outperform” rating and issued a $124.00 target price (up from $110.00) on shares of Stryker Corp. in a research note on Tuesday, July 19th. Canaccord Genuity reiterated a “buy” rating and issued a $130.00 target price on shares of Stryker Corp. in a research note on Sunday, July 24th. Finally, Brean Capital reiterated a “buy” rating and issued a $125.00 target price (up from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $117.91.

Several hedge funds have recently made changes to their positions in the company. LSV Asset Management bought a new stake in shares of Stryker Corp. during the second quarter valued at approximately $107,000. Global X Management Co. LLC increased its stake in shares of Stryker Corp. by 235.8% in the second quarter. Global X Management Co. LLC now owns 994 shares of the medical technology company’s stock valued at $119,000 after buying an additional 698 shares during the period. Carroll Financial Associates Inc. increased its stake in shares of Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock valued at $130,000 after buying an additional 476 shares during the period. CWM LLC bought a new stake in shares of Stryker Corp. during the second quarter valued at approximately $150,000. Finally, Daiwa SB Investments Ltd. bought a new stake in shares of Stryker Corp. during the third quarter valued at approximately $163,000. 75.50% of the stock is owned by institutional investors.

About Stryker Corp.

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.